Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Applied Genetic Technologies initiated with a Buy at Rodman & Renshaw; tgt $16 (7.50)Rodman & Renshaw initiates AGTC with a Buy and price target of $16. AGTC's AAV (adeno-associated virus) platform is based on a proprietary viral composition and manufacturing process that are backed by strong intellectual property positions. AGTC has the capability to target specific tissue types and drive gene expression appropriate for that tissue. <strong>Firm believes that there is great potential to treat an array of disorders that are monogenic (single gene) and autosomal recessive or X-linked.</strong> Co is currently targeting orphan ophthalmological indications with the goal of addressing the underlying biology of the disorder.</td> </tr></table>"